The fourth-generation Calcium channel blocker: Cilnidipine
نویسندگان
چکیده
منابع مشابه
Cilnidipine: Next Generation Calcium Channel Blocker.
Hypertension is one of the most common conditions seen in primary care and a major public health problem in India. It can lead to various complications if not detected early and treated appropriately. As per the latest Eighth Joint National Committee (JNC 8) the goal BP in most hypertensive patients age <60 years should be <140/90 mmHg and treatment can be started by selecting drugs from among ...
متن کاملEvaluation of Mutagenicity of Mebudipine, a New Calcium Channel Blocker
Mebudipine is a new dihydropyridine calcium channel blocker, synthesized in our laboratory, for treatment of hypertension. It has shown a better efficacy than other drugs in this group. For assessing the risks of this drug, certain safety tests in the preclinical stage have been performed. In this study mutagenic effect of mebudipine was evaluated using Ames assay that could assess the mutageni...
متن کاملCalcium-Channel Blocker Overdose
1522-8401/$ see fro doi:10.1016/j.cpem.2 Department of Eme Children’s Hospit RI 02903, USA. Reprint requests and Department of E Children’s Hospit RI 02903, USA. Calcium-channel blockers (CCB) were first developed in the 1960s. Since then, the list of formulations and variety of uses has increased significantly. Unfortunately, toxic exposures to CCBs have also increased since their debut. This ...
متن کاملEvaluation of Mutagenicity of Mebudipine, a New Calcium Channel Blocker
Mebudipine is a new dihydropyridine calcium channel blocker, synthesized in our laboratory, for treatment of hypertension. It has shown a better efficacy than other drugs in this group. For assessing the risks of this drug, certain safety tests in the preclinical stage have been performed. In this study mutagenic effect of mebudipine was evaluated using Ames assay that could assess the mutageni...
متن کاملAntiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease.
Cilnidipine, a dual L-/N-type calcium channel blocker, dilates both efferent and afferent arterioles and is renoprotective. Our multi-center, open-labeled, and randomized trial compared the antiproteinuric effect of cilnidipine with that of amlodipine in hypertensive patients with kidney disease. A group of 339 patients, already receiving renin-angiotensin system inhibitor treatment, were rando...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Heart Journal
سال: 2013
ISSN: 0019-4832
DOI: 10.1016/j.ihj.2013.11.001